Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: Effects of bezafibrate therapy

Journal of Lipid Research

Volumn 44, Issue 8, 2003, Pages 1462-1469

  Jonkers, Iris J A M ^a   Smelt, Augustinus H M ^a   Hattori, Hiroaki ^b   Scheek, Leo M ^c   Van Gent, Teus ^c   De Man, Frits H A F ^a   Van der Laarse, Arnoud ^a   Van Tol, Arie ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b 350 1101   (Japan)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cholesteryl ester transfer; Hypertriglyceridemia; Phospholipid transfer protein; Triglycerides

Indexed keywords

BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PHOSPHOLIPID TRANSFER PROTEIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; BEZAFIBRATE; BLOOD GLUCOSE; CARRIER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN; INSULIN RESISTANCE; LINEAR MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR WEIGHT; PHOSPHOLIPID TRANSFER PROTEINS;

EID: 0142105910     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M300008-JLR200     Document Type: Article

References (43)

1. Austin, M. A., J. E. Hokanson, and K. L. Edwards. 1998. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. 81: 7B-12B.
2. Barter, P. J., and K. A. Rye. 1996. Molecular mechanisms of reverse cholesterol transport. Curr. Opin. Lipidol. 7: 82-87.
3. Navab, M., S. Y. Hama, G. P. Hough, C. C. Hedrick, R. Sorenson, B. N. La Du, J. A. Kobashigawa, G. C. Fonarow, J. A. Berliner, H. Laks, and A. M. Fogelman. 1998. High density associated enzymes: their role in vascular biology. Curr. Opin. Lipidol. 9: 449-456.
4. van Tol, A. 2002. Phospholipid transfer protein. Curr. Opin. Lipidol. 13: 135-139.
5. von Eckardstein, A., M. Jauhiainen, Y. Huang, J. Metso, C. Langer, P. Pussinen, S. Wu, C. Ehnholm, and G. Assmann. 1996. Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre beta 1-HDL. Biochim. Biophys. Acta. 1301: 255-262.
6. Tall, A. R. 1993. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34: 1255-1274.
7. van Haperen, R., A. van Tol, P. Vermeulen, M. Jauhiainen, T. van Gent, P. van den Berg, S. Ehnholm, F. Grosveld, A. van der Kamp, and R. de Crom. 2000. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 20: 1082-1088.
8. Jiang, X. C., S. Qin, C. Qiao, K. Kawano, M. Lin, A. Skold, X. Xiao, and A. R. Tall. 2001. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid transfer protein deficiency. Nat. Med. 7: 847-852.
9. Lie, J., R. de Crom, R. van Haperen, L. Scheek, I. Lankhuizen, and A. van Tol. 2002. Elevation of plasma phopholipid transfer protein in transgenic mice increases VLDL secretion. J. Lipid Res. 43: 1875-1880.
10. van Haperen, R., A. van Tol, T. van Gent, L. Scheek, P. Visser, P. van der Kamp, F. Grosveld, and R. de Crom. 2002. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J. Biol. Chem. 277: 48938-48943.
11. Riemens, S. C., A. van Tol, W. J. Sluiter, and R. P. Dullaart. 1998. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients. Diabetologia. 41: 929-934.
12. Grundy, S. M. 1998. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 81: 18B-25B.
13. Oka, T., T. Kujiraoka, M. Ito, T. Egashira, S. Takahashi, M. N. Nanjee, N. E. Miller, J. Metso, V. M. Ollkonen, C. Ehnholm, M. Jauhiainen, and H. Hattori. 2000. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J. Lipid Res. 41: 1651-1657.
14. Kärkäinen, M., T. Oka, V. M. Ollkonen, J. Metso, H. Hattori, M. Jauhiainen, and C. Ehnholm. 2002. Isolation and partial characterization of the inactive forms of human plasma phospholipid transfer protein (PLTP). J. Biol. Chem. 277: 15413-15418.
15. Murdoch, S. J., M. C. Carr, J. E. Hokanson, J. D. Brunzell, and J. J. Albers. 2000. PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J. Lipid Res. 41: 237-244.
16. Oka, T., M. Ito, T. Kujiraoka, M. Nagano, M. Ishihara, T. Iwasaki, T. Egashira, N. E. Miller, and H. Hattori. 2000. Measurement of human plasma phospholipid transfer protein by sandwich enzyme-linked immunosorbent assay. Clin. Chem. 46: 1357-1364.
17. Matthews, D. R., J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28: 412-419.
18. Channon, K. M., R. J. Clegg, D. Bhatnagar, M. Ishola, S. Arrol, and P. N. Durrington. 1990. Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer. Atherosclerosis. 80: 217-226.
19. Sutherland, W. H., R. J. Walker, N. J. Lewis-Barned, H. Pratt, and H. C. Tillman. 1994. Plasma cholesteryl ester transfer in patients with non-insulin dependent diabetes mellitus. Clin. Chim. Acta. 231: 29-38.
20. Dullaart, R. P., W. J. Sluiter, L. D. Dikkeschei, K. Hoogenberg, and A. van Tol. 1994. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur. J. Clin. Invest. 24: 188-194.
21. Hannuksela, M., Y. L. Marcel, Y. A. Kesaniemi, and M. J. Savolainen. 1992. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J. Lipid Res. 33: 737-744.
22. Speijer, H., J. E. Groener, E. van Ramshorst, and A. van Tol. 1991. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis. 90: 159-168.
23. Jansen, H., W. Hop, A. van Tol, A. V. Bruschke, and J. C. Birkenhager. 1994. Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease. Atherosclerosis. 107: 45-54.
24. Murakami, T., S. Michelagnoli, R. Longhi, G. Gianfranceschini, F. Pazzucconi, L. Calabresi, C. R. Sirtori, and G. Franceschini. 1995. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler. Thromb. Vasc. Biol. 15: 1819-1828.
25. Mann, C. J., F. T. Yen, A. M. Grant, and B. E. Bihain. 1991. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J. Clin. Invest. 88: 2059-2066.
26. Mostaza, J. M., G. L. Vega, P. Snell, and S. M. Grundy. 1998. Abnormal metabolism of free fatty acids in hypertriglyceridaemic men: apparent insulin resistance of adipose tissue. J. Intern. Med. 243: 265-274.
27. Lagrost, L., E. Florentin, V. Guyard-Dangremont, A. Athias, H. Gandjini, C. Lallemant, and P. Gambert. 1995. Evidence for nonesterified fatty acids as modulators of neutral lipid transfers in normolipidemic human plasma. Arterioscler. Thromb. Vasc. Biol. 15: 1388-1396.
28. Desrumaux, C., A. Athias, G. Bessede, B. Verges, M. Farnier, L. Persegol, P. Gambert, and L. Lagrost. 1999. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler. Thromb. Vasc. Biol. 19: 266-275.
29. Colhoun, H. M., M. R. Taskinen, J. D. Otvos, P. van den Berg, J. O'Connor, and A. van Tol. 2002. Relationship of phospholipid transfer protein activity to HDL and apo B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes. 51: 3300-3305.
30. Oka, T., S. Yamashita, T. Kujiraoka, M. Ito, N. Nagano, Y. Sagehashi, T. Egashira, M. N. Nanjee, K. Hirano, N. E. Miller, Y. Matzusawa, and H. Hattori. 2002. Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia. J. Lipid Res. 43: 1236-1243.
31. Huuskonen, J., M. Ekström, E. Tahvanainen, A. Vainio, J. Metso, P. Pussinen, C. Ehnholm, V. M. Olkkonen, and M. Jauhiainen. 2000. Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis. 151: 451-461.
32. Wolfbauer, G., J. J. Albers, and J. F. Oram. 1999. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apoproteins. Biochim. Biophys. Acta. 1439: 65-75.
33. Laffitte, B. A., S. B. Joseph, M. Chen, A. Castrillo, J. Repa, D. Wilpitz, D. Mangelsdorf, and P. Tontonoz. 2003. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell. Biol. 23: 2182-2191.
34. Bouly, M., D. Masson, B. Gross, X. C. Jiang, C. Fievet, G. Castro, A. R. Tall, J. C. Fruchart, B. Staels, L. Lagrost, and G. Luc. 2001. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J. Biol. Chem. 276: 25841-25847.
35. Zambrana, J. L., F. Velasco, P. Castro, M. Concha, F. Valles, P. Montilla, J. A. Jimenez-Pereperez, J. Lopez-Miranda, and F. Perez-Jimeniz. 1997. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. Am. J. Cardiol. 80: 836-840.
36. Jones, I. R., A. Swai, R. Taylor, M. Miller, M. F. Laker, and K. G. Alberti. 1990. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care. 13: 855-863.
37. Homma, Y., H. Ozawa, T. Kobayashi, H. Yamaguchi, H. Sakane, Y. Mikami, and H. Nakamura. 1994. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis. 106: 191-201.
38. Guerin, M., E. Bruckert, P. J. Dophin, and M. J. Chapman. 1996. Fenofibrate reduces plasma CETP mass and activity and normalises the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 16: 763-772.
39. Kahri, J., T. Sane, A. van Tol, and M. Taskinen. 1995. Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridemic patients. J. Intern. Med. 238: 429-436.
40. Tu, A., and J. J. Albers. 2001. Glucose regulated the transcription of human genes relevant to HDL metabolism. Responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes. 50: 1851-1856.
41. Riemens, S. C., A. Van Tol, W. J. Sluiter, and R. P. F. Dullaart. 1999. Acute and chronic effects of a 24-hour intravenous triglyceride emulsion challenge on plasma LCAT, PLTP, and CETP activities. J. Lipid Res. 40: 1459-1466.
42. Jiang, X. C., C. Bruce, J. Mar, M. Lin, Y. Ji, O. L. Francone, and A. R. Tall. 1999. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 103: 907-914.
43. Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J. C. Fruchart. 1998. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98: 2088-2093.